CDC42BPA antibody | knockout validation | Abnova H00008476-M01

This is a knockout-validated antibody summary, based on the publication "Discovery of potent and selective MRCK inhibitors with therapeutic effect on skin cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG1,kappa

Company: Abnova

Antibody: CDC42BPA

Catalog number: H00008476-M01

Summary: Mouse monoclonal IgG1,kappa against a partial recombinant CDC42BPA (551 a.a. ~ 650 a.a). Reacts with human by western blot and ELISA.

Validation Method

Western blot

Sample

Control and MRCKαβ double knockout MDA MB 231 cells.

Secondary incubation

Goat anti-mouse IgG Dylight 800 (35521; Thermo Scientific) or goat anti-mouse IgG IR Dye 680 (926-68020; LI-COR Biosciences).

Figure

Western blots from parental and MRCKαβ double CRISPR/Cas9 knockout (KO) MDA MB 231 cells that were blotted for total MRCK, αTubulin, MRCKα, MRCKβ, ERK2 or Cas9 as indicated. Please see Figure S4a in the article [1].

Clone note

The same clone (1G7) is sold as LifeSpan Biosciences LS-C198572; Abnova H00008476-M01; Sigma-Aldrich WH0008476M1.

References
  1. Unbekandt M, Belshaw S, Bower J, Clarke M, Cordes J, Crighton D, et al. Discovery of potent and selective MRCK inhibitors with therapeutic effect on skin cancer.. Cancer Res. 2018;0: pubmed publisher